Singapore markets closed
Straits Times Index
3,240.58 +49.87 (+1.56%) Nikkei
26,739.03 +336.19 (+1.27%) Hang Seng
20,717.24 +596.56 (+2.96%) FTSE 100
7,389.98 +87.24 (+1.19%) BTC-USD
29,535.90 +606.12 (+2.10%) CMC Crypto 200
650.34 -23.03 (-3.42%)
SpringWorks Therapeutics, Inc. (SWTX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 35.42 |
| Open | 36.27 |
| Bid | 14.64 x 800 |
| Ask | 48.00 x 800 |
| Day's range | 35.19 - 37.59 |
| 52-week range | 33.33 - 89.75 |
| Volume | |
| Avg. volume | 499,058 |
| Market cap | 1.838B |
| Beta (5Y monthly) | 1.00 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma
DURHAM, N.C. & STAMFORD, Conn., June 28, 2021--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in the combination
© 2022 Yahoo. All rights reserved.
